| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biological Chemistry and Molecular Pharmacology and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [T. K. H. C., G. F. W., D. J. W.], and Gentest Corporation, Woburn, Massachusetts 01801 [C. L. C.]
2 To whom correspondence should be addressed, at Dana-Farber Cancer Institute, Room JF-525, 44 Binney Street, Boston, MA 02115.
The present study identifies the specific human cytochrome P-450 (CYP) enzymes involved in hydroxylation leading to activation of the anticancer drug cyclophosphamide and its isomeric analogue, ifosphamide. Substantial interindividual variation (4-9-fold) was observed in the hydroxylation of these oxazaphosphorines by a panel of 12 human liver microsomes, and a significant correlation was obtained between these 2 activities (r = 0.85, P < 0.001). Enzyme kinetic analyses revealed that human liver microsomal cyclophosphamide 4-hydroxylation and ifosphamide 4-hydroxylation are best described by a 2-component MichaelisMenten model composed of both low Km and high Km P-450 4-hydroxylases. To ascertain whether one or more human P-450 enzymes are catalytically competent in activating these oxazaphosphorines, microsomal fractions prepared from a panel of human B-lymphoblastoid cell lines stably transformed with individual P-450 complementary DNAs were assayed in vitro for oxazaphosphorine activation. Expressed CYP2A6, -2B6, -2C8, -2C9, and -3A4 were catalytically competent in hydroxylating cyclophosphamide and ifosphamide. Whereas CYP2C8 and CYP2C9 have the characteristics of low Km oxazaphosphorine 4-hydroxylases, CYP2A6, -2B6, and -3A4 are high Km forms. In contrast, CYP1A1, -1A2, -2D6, and -2E1 did not produce detectable activities. Furthermore, growth of cultured CYP2A6- and CYP2B6-expressing B-lymphoblastoid cells, but not of CYP-negative control cells, was inhibited by cyclophosphamide and ifosphamide as a consequence of prodrug activation to cytotoxic metabolites. Experiments with P-450 form-selective chemical inhibitors and inhibitory anti-P-450 antibodies were then performed to determine the contributions of individual P-450s to the activation of these drugs in human liver microsomes. Orphenadrine (a CYP2B6 inhibitor) and anti-CYP2B IgG inhibited microsomal cyclophosphamide hydroxylation to a greater extent than ifosphamide hydroxylation, consistent with the 8-fold higher activity of complementary DNA-expressed CYP2B6 with cyclophosphamide. In contrast, troleandomycin, a selective inhibitor of CYP3A3 and -3A4, and anti-CYP3A IgG substantially inhibited microsomal ifosphamide hydroxylation but had little or no effect on microsomal cyclophosphamide hydroxylation. By contrast, the CYP2D6-selective inhibitor quinidine did not affect either microsomal activity, while anti-CYP2A antibodies had only a modest inhibitory effect. Overall, the present study establishes that liver microsomal CYP2B and CYP3A preferentially catalyze cyclophosphamide and ifosphamide 4-hydroxylation, respectively, suggesting that liver P-450-inducing agents targeted at these enzymes might be used in cancer patients to enhance drug activation and therapeutic efficacy.
1 Supported in part by Grant CA-49248 from the NIH (D. J. W.). T. K. H. C. was supported by a Canadian Liver Foundation Research Fellowship and G. F. W. by a Deutsche Forschungsgemeinschaft Postdoctoral Fellowship.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 7/ 2/93. Accepted 9/28/93.
This article has been cited by other articles:
|
|
 |
|
  A. J. Lau and T. K. H. Chang Inhibition of Human CYP2B6-Catalyzed Bupropion Hydroxylation by Ginkgo biloba Extract: Effect of Terpene Trilactones and Flavonols Drug Metab. Dispos., September 1, 2009; 37(9): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. O'Donnell and M. E. Dolan Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy Clin. Cancer Res., August 1, 2009; 15(15): 4806 - 4814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Storme, A. Deroussent, L. Mercier, E. Prost, M. Re, F. Munier, T. Martens, P. Bourget, G. Vassal, J. Royer, et al. New Ifosfamide Analogs Designed for Lower Associated Neurotoxicity and Nephrotoxicity with Modified Alkylating Kinetics Leading to Enhanced in Vitro Anticancer Activity J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 598 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. McLaughlin, L. J. Dickmann, C. R. Wolf, and C. J. Henderson Functional Expression and Comparative Characterization of Nine Murine Cytochromes P450 by Fluorescent Inhibition Screening Drug Metab. Dispos., July 1, 2008; 36(7): 1322 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Hofmann, J. K. Blievernicht, K. Klein, T. Saussele, E. Schaeffeler, M. Schwab, and U. M. Zanger Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 284 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky and R. S. Obach A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1',1''-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6 Drug Metab. Dispos., November 1, 2007; 35(11): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Afsharian, Y. Terelius, Z. Hassan, C. Nilsson, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats Clin. Cancer Res., July 15, 2007; 13(14): 4218 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tsai-Turton, B. T. Luong, Y. Tan, and U. Luderer Cyclophosphamide-Induced Apoptosis in COV434 Human Granulosa Cells Involves Oxidative Stress and Glutathione Depletion Toxicol. Sci., July 1, 2007; 98(1): 216 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Blievernicht, E. Schaeffeler, K. Klein, M. Eichelbaum, M. Schwab, and U. M. Zanger MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms Clin. Chem., January 1, 2007; 53(1): 24 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Hesse, D. J. Greenblatt, L. L. von Moltke, and M. H. Court Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J. Clin. Pharmacol., May 1, 2006; 46(5): 567 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-D. Marechal, J. Yu, S. Brown, I. Kapelioukh, E. M. Rankin, C. R. Wolf, G. C. K. Roberts, Mark. J. I. Paine, and M. J. Sutcliffe IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER Drug Metab. Dispos., April 1, 2006; 34(4): 534 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-S. Chen, Y. Jounaidi, and D. J. Waxman ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450 Drug Metab. Dispos., September 1, 2005; 33(9): 1261 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al. Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kumar, C. S. Chen, D. J. Waxman, and J. R. Halpert Directed Evolution of Mammalian Cytochrome P450 2B1: MUTATIONS OUTSIDE OF THE ACTIVE SITE ENHANCE THE METABOLISM OF SEVERAL SUBSTRATES, INCLUDING THE ANTICANCER PRODRUGS CYCLOPHOSPHAMIDE AND IFOSFAMIDE J. Biol. Chem., May 20, 2005; 280(20): 19569 - 19575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lu, S. B. Singh, B. A. Carr, Y. Fang, C. D. Xiang, T. H. Rushmore, A. D. Rodrigues, and M. Shou Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12 J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 518 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M. D. Forster, R. Gibson, A. Makris, D. C. Talbot, J. Steiner, et al. Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma Clin. Cancer Res., February 15, 2005; 11(4): 1512 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Futatsugawa, T. Kubota, A. Ishiguro, H. Suzuki, H. Ishikawa, and T. Iga PCR-Based Haplotype Determination to Distinguish CYP2B6*1/*7 and *5/*6 Clin. Chem., August 1, 2004; 50(8): 1472 - 1473. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Jacob, E. C. Johnstone, M. J. Neville, and R. T. Walton Identification of CYP2B6 Sequence Variants by Use of Multiplex PCR with Allele-Specific Genotyping Clin. Chem., August 1, 2004; 50(8): 1372 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-S. Chen, J. T. Lin, K. A. Goss, Y.-a. He, J. R. Halpert, and D. J. Waxman Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics Mol. Pharmacol., May 1, 2004; 65(5): 1278 - 1285. [Abstract] [Full Text]
|
|
|
|
|
|
R. Qiu, T. F. Kalhorn, and J. T. Slattery ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1204 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Marr, W. Leisenring, F. Crippa, J. T. Slattery, L. Corey, M. Boeckh, and G. B. McDonald Cyclophosphamide metabolism is affected by azole antifungals Blood, February 15, 2004; 103(4): 1557 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Jones Overcoming Methodological Weakness in Dose-Intense Alkylating Agent Studies through Pharmacology Clin. Cancer Res., January 15, 2004; 10(2): 413 - 414. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Mace, M. L. Keohan, H. Bernardy, K. Junge, G. Niebch, P. Romeis, A. Thoma, T. Wagner, U. Mueller, G. Demetri, et al. Crossover Randomized Comparison of Intravenous versus Intravenous/Oral Mesna in Soft Tissue Sarcoma Treated with High-Dose Ifosfamide Clin. Cancer Res., December 1, 2003; 9(16): 5829 - 5834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jinno, T. Tanaka-Kagawa, A. Ohno, Y. Makino, E. Matsushima, N. Hanioka, and M. Ando Functional Characterization of Cytochrome P450 2B6 Allelic Variants Drug Metab. Dispos., April 1, 2003; 31(4): 398 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. H. Chang, S. M. Bandiera, and J. Chen Constitutive Androstane Receptor and Pregnane X Receptor Gene Expression in Human Liver: Interindividual Variability and Correlation with CYP2B6 mRNA Levels Drug Metab. Dispos., January 1, 2003; 31(1): 7 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Fan, C. Gu, S. A. Marsh, and J. C. Stevens Mechanism-Based Inactivation of Cytochrome P450 2B6 by a Novel Terminal Acetylene Inhibitor Drug Metab. Dispos., January 1, 2003; 31(1): 28 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cancino-Badias, R.E. Reyes, R. Nosti, I. Perez, V. Dorado, S. Caballero, A. Soria, R. Camacho-Carranza, D. Escobar, and J.J. Espinosa-Aguirre Modulation of rat liver citochrome P450 by protein restriction assessed by biochemical and bacterial mutagenicity methods Mutagenesis, January 1, 2003; 18(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H Palmer, M.-J. Chen, and D. J Kerr Gene therapy for colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 201 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lindley, G. Hamilton, J. S. McCune, S. Faucette, S. S. Shord, R. L. Hawke, H. Wang, D. Gilbert, S. Jolley, B. Yan, et al. The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes Drug Metab. Dispos., July 1, 2002; 30(7): 814 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Escobar-Garcia, R. Camacho-Carranza, I. Perez, V. Dorado, M. Arriaga-Alba, and J.J. Espinosa-Aguirre S9 induction by the combined treatment with cyclohexanol and albendazole Mutagenesis, November 1, 2001; 16(6): 523 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yanagihara, S. Kariya, M. Ohtani, K. Uchino, T. Aoyama, Y. Yamamura, and T. Iga Involvement of CYP2B6 in N-Demethylation of Ketamine in Human Liver Microsomes Drug Metab. Dispos., June 1, 2001; 29(6): 887 - 890. [Abstract] [Full Text]
|
|
|
|
|
|
K. I. Hirsch-Ernst, K. Schlaefer, D. Bauer, A. F. Heder, and G. F. Kahl Repression of Phenobarbital-Dependent CYP2B1 mRNA Induction by Reactive Oxygen Species in Primary Rat Hepatocyte Cultures Mol. Pharmacol., June 1, 2001; 59(6): 1402 - 1409. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Hamaoka, Y. Oda, I. Hase, and A. Asada Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies Br. J. Anaesth., April 1, 2001; 86(4): 540 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Yu, J. Matias, D. A. Scudiero, K. M. Hite, A. Monks, E. A. Sausville, and D. J. Waxman P450 Enzyme Expression Patterns in the NCI Human Tumor Cell Line Panel Drug Metab. Dispos., March 1, 2001; 29(3): 304 - 312. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Ariyoshi, S. Imaoka, K. Nakayama, Y. Takahashi, K.-I. Fujita, Y. Funae, and T. Kamataki Comparison of the Levels of Enzymes Involved in Drug Metabolism between Transgenic or Gene-knockout and the Parental Mice Toxicol Pathol, January 1, 2001; 29(1_suppl): 161 - 172. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Zhou, Y. Lu, M. S. Steiner, and J. T. Dalton Cytochrome P-450 2C9 Sensitizes Human Prostate Tumor Cells to Cyclophosphamide via a Bystander Effect Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2659 - 2663. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Hesse, K. Venkatakrishnan, M. H. Court, L. L. von Moltke, S. X. Duan, R. I. Shader, and D. J. Greenblatt CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants Drug Metab. Dispos., October 1, 2000; 28(10): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jounaidi and D. J. Waxman Combination of the Bioreductive Drug Tirapazamine with the Chemotherapeutic Prodrug Cyclophosphamide for P450/P450-Reductase-based Cancer Gene Therapy Cancer Res., July 1, 2000; 60(14): 3761 - 3769. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Rosario, M. L. O'Brien, C. J. Henderson, C. R. Wolf, and K. D. Tew Cellular Response to a Glutathione S-Transferase P1-1 Activated Prodrug Mol. Pharmacol., July 1, 2000; 58(1): 167 - 174. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y.-J. Y. Wan, D. An, Y. Cai, J. J. Repa, T. Hung-Po Chen, M. Flores, C. Postic, M. A. Magnuson, J. Chen, K. R. Chien, et al. Hepatocyte-Specific Mutation Establishes Retinoid X Receptor alpha as a Heterodimeric Integrator of Multiple Physiological Processes in the Liver Mol. Cell. Biol., June 15, 2000; 20(12): 4436 - 4444. [Abstract] [Full Text]
|
|
|
|
|
|
L. Quintieri, A. Rosato, E. Napoli, F. Sola, C. Geroni, M. Floreani, and P. Zanovello In Vivo Antitumor Activity and Host Toxicity of Methoxymorpholinyl Doxorubicin: Role of Cytochrome P450 3A Cancer Res., June 1, 2000; 60(12): 3232 - 3238. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, S. Abe, M. Nakajima, N. Shimada, M. Tani, K. Chiba, and T. Yamamoto Role of Human CYP2B6 in S-Mephobarbital N-Demethylation Drug Metab. Dispos., December 1, 1999; 27(12): 1429 - 1433. [Abstract] [Full Text]
|
|
|
|
|
|
P. Roy, O. Tretyakov, J. Wright, and D. J. Waxman Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of R-Enantiomer Drug Metab. Dispos., November 1, 1999; 27(11): 1309 - 1318. [Abstract] [Full Text]
|
|
|
|
|
|
T. L. Domanski, K. M. Schultz, F. Roussel, J. C. Stevens, and J. R. Halpert Structure-Function Analysis of Human Cytochrome P-450 2B6 Using a Novel Substrate, Site-Directed Mutagenesis, and Molecular Modeling J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1141 - 1147. [Abstract] [Full Text]
|
|
|
|
|
|
C. Teyssier, L. Guenot, M. Suschetet, and M.-H. Siess Metabolism of Diallyl Disulfide by Human Liver Microsomal Cytochromes P-450 and Flavin-Containing Monooxygenases Drug Metab. Dispos., July 1, 1999; 27(7): 835 - 841. [Abstract] [Full Text]
|
|
|
|
|
|
P. Roy, L. J. Yu, C. L. Crespi, and D. J. Waxman Development of a Substrate-Activity Based Approach To Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles Drug Metab. Dispos., June 1, 1999; 27(6): 655 - 666. [Abstract] [Full Text]
|
|
|
|
|
|
C. P. Granvil, A. Madan, M. Sharkawi, A. Parkinson, and I. W. Wainer Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of (R)- and (S)-Ifosfamide in Human Liver Microsomes Drug Metab. Dispos., April 1, 1999; 27(4): 533 - 541. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Nicoll-Griffith, J.-P. Falgueyret, J. M. Silva, P.-E. Morin, L. Trimble, C.-C. Chan, S. Clas, S. Leger, Z. Wang, J. A. Yergey, et al. Oxidative Bioactivation of the Lactol Prodrug of A Lactone Cyclooxygenase-2 Inhibitor Drug Metab. Dispos., March 1, 1999; 27(3): 403 - 409. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Yule, D. Walker, M. Cole, L. McSorley, S. Cholerton, A. K. Daly, A.D.J. Pearson, and A. V. Boddy The Effect of Fluconazole on Cyclophosphamide Metabolism in Children Drug Metab. Dispos., March 1, 1999; 27(3): 417 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. Yu, P. Drewes, K. Gustafsson, E. G. C. Brain, J. E. D. Hecht, and D. J. Waxman In Vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 928 - 937. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. A. Felix, A. H. Walker, B. J. Lange, T. M. Williams, N. J. Winick, N.-K. V. Cheung, B. D. Lovett, P. C. Nowell, I. A. Blair, and T. R. Rebbeck Association of CYP3A4 genotype with treatment-related leukemia PNAS, October 27, 1998; 95(22): 13176 - 13181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lu, J. J. Wang, K. K. Chan, and D. Young Effects of Phenobarbital on Stereoselective Metabolism of Ifosfamide in Rats Drug Metab. Dispos., May 1, 1998; 26(5): 476 - 482. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Stevens, R. B. White, S. H. Hsu, and M. Martinet Human Liver CYP2B6-Catalyzed Hydroxylation of RP 73401 J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1389 - 1395. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Messina, R. F. Tyndale, and E. M. Sellers A Major Role for CYP2A6 in Nicotine C-Oxidation by Human Liver Microsomes J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1608 - 1614. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Code, C. L. Crespi, B. W. Penman, F. J. Gonzalez, T. K. H. Chang, and D. J. Waxman Human Cytochrome P4502B6. Interindividual Hepatic Expression, Substrate Specificity, and Role in Procarcinogen Activation Drug Metab. Dispos., August 1, 1997; 25(8): 985 - 993. [Abstract] [Full Text]
|
|
|
|
|
|
D. Sutton, A. M. Butler, L. Nadin, and M. Murray Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 294 - 300. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Guo, S. Raeissi, R. B. White, and J. C. Stevens Orphenadrine and Methimazole Inhibit Multiple Cytochrome P450 Enzymes in Human Liver Microsomes Drug Metab. Dispos., March 1, 1997; 25(3): 390 - 393. [Abstract] [Full Text]
|
|
|
|
|
|
A. M. Butler and M. Murray Biotransformation of Parathion in Human Liver: Participation of CYP3A4 and its Inactivation during Microsomal Parathion Oxidation J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 966 - 973. [Abstract] [Full Text]
|
|
|
|
|
|
K. D. Bunting and A. J. Townsend De Novo Expression of Transfected Human Class 1 Aldehyde Dehydrogenase (ALDH) Causes Resistance to Oxazaphosphorine Anti-cancer Alkylating Agents in Hamster V79 Cell Lines J. Biol. Chem., May 17, 1996; 271(20): 11884 - 11890. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
